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Introduction
Central nervous system (CNS) involvement is common
in cryopyrin-associated periodic syndromes (CAPS),
especially in children. Neurological manifestations of the
low-penetrance cryopyrin mutations V198M and Q703K
encoded by exon 3 of the NLRP3 gene have not been
investigated so far.
Objectives
To determine the frequency of the V198M and Q703K
substitutions in adult patients with possible inflammatory
CNS disease and at least two symptoms compatible with
CAPS and to describe the clinical phenotype of muta-
tion-positive patients.
Methods
94 unrelated, consecutive patients with possible inflamma-
tory CNS disease and at least two symptoms compatible
CAPS were prospectively screened for the V198M and
Q703K mutations. In addition, the clinical, laboratory, and
MRI features of mutation carriers were assessed.
Results
15 patients (16%; 12 females) were identified to carry one
of the two low-penetrance mutations in exon 3 of the
NLRP3 gene (V198M: n= 2; Q703K: n =13). CAPS-asso-
ciated systemic symptoms consisted of recurrent inflam-
mation of the eyes, arthralgias, myalgias, urticarial rash,
abdominal pain, and severe fatigue. CNS manifestation
included optic nerve inflammation and/or atrophy, cranial
nerve palsy, migraine, recurrent meningitis, and senso-
neurinal hypacusis. Eight patients (53%) fulfilled the diag-
nostic criteria for multiple sclerosis (MS) according to the
McDonald criteria. Brain magnetic resonance imaging
(MRI) showed abnormalities in all but one patient.
Conclusion
So far, the V198M and Q703K mutations have been only
rarely described in association with MS or CNS inflam-
mation. We observed a a surprisingly high frequency of
these two low-penetrance mutations in the cohort stu-
died, leading to a heterogeneous pattern of CNS manifes-
tations in affected patients. Thus, molecular genetic
testing should be considered in patients with an unusual
CNS inflammation and/or MS, who report additional
symptoms compatible with CAPS.
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